ESR1 and triple-negative breast carcinoma: Although many treatment options are available for estrogen receptor–positive (ER+) tumors, ER-negative (ER−) and triple negative breast cancer (TNBC) subtypes are the most clinically challenging malignancies due to limited treatment options (1).